Such collaborations may take different forms: delivering novel monoclonal antibodies or other biologics to their intracellular target; improving the biodistribution of novel small molecules with ...

Notably, intracellular checkpoint molecules within ... These molecules offer a universal target for cancer immunotherapy, as their impact on antitumor immunity is consistent across different ...

A number of research firms recently weighed in on ITCI. UBS Group dropped their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a ...

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, ...

Natural killer (NK) cells play an important role in the innate immune response to cancer and viral infections, and their ...

Brian Abrahams highlighted Intra-Cellular Therapies (ITCI) due to its commercial infrastructure and Karuna Therapeutics (KRTX) for phase 3 candidate KarXT for schizophenia and psychosis in ...

Notably, intracellular checkpoint molecules within ... These molecules offer a universal target for cancer immunotherapy, as their impact on antitumor immunity is consistent across different ...

Unlike CAR-T cells, which require surface antigens for recognition and may have limitations in target accessibility, TCRs recognize a broader range of targets including intracellular proteins like ...